Lorcaserin
As of the edition of 20 October 2026, Lorcaserin is a small molecule: withdrawn from the market in 2020; acts on HTR2C; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2020
- Kind
- Small molecule
- Brand name
- Belviq
- First approved
- 27 June 2012 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Eisai
- Withdrawn from market
- 1 January 2020 (in some regions)
- Registered trials
- 42, 10 stopped early
- Disease areas
- Nutrition and metabolism; Chemically induced; Mental health; Nervous system; Heart and blood vessels; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Lorcaserin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR2C | 5-hydroxytryptamine receptor 2C | P28335 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 17 | 15 | 0 | 2 |
| Phase 2 | 11 | 6 | 0 | 3 |
| Phase 3 | 7 | 4 | 0 | 3 |
| Phase 4 | 5 | 2 | 0 | 2 |
| All trials | 42 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eisai | Originator and Lead sponsor of trials | 2012 to now |